Liquidia(NASDAQ) LQDA

Liquidia helps people with rare lung and blood vessel diseases. They make medicines that patients inhale to breathe easier. These treatments help patients manage their health at home using small devices.

The Medicine Cabinet

• YUTREPIA: Inhaled dry powder used to treat high blood pressure in the lung arteries and high blood pressure caused by lung scarring.
• Generic Treprostinil: Liquid medicine for lung diseases sold through a profit-sharing agreement with Sandoz.
• PRINT Technology: Proprietary engineering platform that creates uniform drug particles for better delivery into the lungs.
• L606: Experimental liquid medicine currently being tested in clinical trials for patients with chronic lung conditions.

New Partnerships and Bigger Labs

• Started commercial sales of YUTREPIA in June 2025 following approval from the U.S. Food and Drug Administration.
• Signed an exclusive licensing deal with Vectura Limited in October 2025 for new drug delivery technology.
• Licensed the drug L606 from Pharmosa Biopharm Inc. to expand the company's range of respiratory treatments.
• Entered a new lease for a second manufacturing facility in Morrisville in June 2025 to increase production capacity.

Precise Particles for Better Care

Liquidia uses its own particle technology to deliver high doses of medicine through a small, low-effort inhaler. This allows patients to get necessary treatment without using large or complex hospital equipment.

Momentum by the Numbers

• Total revenue hit $132.9 million in Q1 2026, up 4158.5% from $3.1 million in Q1 2025.
• Net income reached $52.9 million in Q1 2026, which turned positive and improved from a $38.4 million loss.
• Operating cash flow improved to $53 million in Q1 2026, up from a cash burn of $30.7 million.
• Free cash flow reached $50.2 million in Q1 2026, turning positive from a $31 million loss in Q1 2025.

Bottom Line

Liquidia has transitioned from a research firm into a profitable commercial business focused on respiratory health. Its unique drug delivery technology and successful product launch have established a new foundation for long-term operations.